Abstract
The potential risk of drug‐induced prolongation of the electrocardiographic QT interval has been a clinical concern with some drug classes due to the increased risk of developing a rare but life‐threatening atypical ventricular tachycardia known as torsades de pointes. This has led to the withdrawal of several drugs from the U.S. market, as well as a Drug Safety Communication issued by the Food and Drug Administration for citalopram, which is commonly prescribed off‐label for management of anxiety in patients with post‐traumatic stress disorder (PTSD).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
